-
-
-
-
-
-
-
Scholar Rock resubmits drug application to FDA for SMA treatment
-
-
-
-
-
-
-
Scholar Rock (SRRK) PT Raised to $53 at Barclays
-
-
-
-
-
-
-
Citi Starts Scholar Rock (SRRK) at Buy
-
-
-
-
-
-
-
Truist Securities Reiterates Buy Rating on Scholar Rock (SRRK)
-
-
-
-
-
-
-
Scholar Rock (SRRK) PT Lowered to $44 at Barclays
-
-
-
-
-
-
-
Scholar Rock (SRRK) PT Lowered to $45 at BMO Capital
-
-
-
-
-
-
-
Scholar Rock Holding (SRRK) Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss
-
416,808 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

